Previous 10 | Next 10 |
Zynex Announces 2022 Third Quarter Earnings PR Newswire ENGLEWOOD, Colo. , Oct. 27, 2022 /PRNewswire/ -- Zynex, Inc . (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...
Zynex, Inc. to Announce Third Quarter 2022 Financial Results PR Newswire ENGLEWOOD, Colo. , Oct. 13, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive me...
Zynex ( NASDAQ: ZYXI ) on Tuesday reported record order growth in Q3 and reiterated its guidance. Q3 orders increased 34% Y/Y and 12% sequentially. "Aug. and Sept. saw the highest number of monthly orders in ZYXI's history. Additionally, cash collections ...
Zynex Reports Preliminary Third Quarter 2022 Results PR Newswire ENGLEWOOD, Colo. , Oct. 11, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical de...
The number one fact in play right now for investors is risk aversion. According to Bank of America strategists, professional money managers are currently sitting on their highest cash allocation levels ever. According Sentimentrader.com, large investors are currently sitting on their largest ...
Summary Zynex has succumbed to extensive short selling in 2021-22 that may be in the process of reconsidering bearish bets. Projected growth rates for the company are exceptionally positive, on new product releases. Valuations are extremely low if analyst estimates prove corre...
Summary DPNCheck is a screening product sold to MA insurers which gives better member health outcomes, lower cost, and increased revenue for MA insurers. The product has consistently grown >20%. Discontinuation of Quell marketing in 2018 is masking the strong, underlying growth...
Zynex ( NASDAQ: ZYXI ) announced it had begun enrollments to test its second generation monitoring system, CM-1600, in a large-scale blood loss detection trial. The multi-site trial, first initiated with ClinCept, is designed to determine the specificity and sensitivity of the...
Zynex Monitoring Solutions Announces First Enrollment in a Blood Loss Detection Clinical Trial for its CM-1600 Monitoring System PR Newswire ENGLEWOOD, Colo. , Sept. 21, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology com...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion. They also tend to be riskier than large-cap names. Revenue and...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to announce the company's financial and operational results for the second quarter ending June 30, 2024, in an interview with Proactive. The company achieved a remarkable 20% year-over-year increase in orde...
2024-07-26 16:37:00 ET Shares of pain-management equipment specialist Zynex (NASDAQ: ZYXI) were falling in Friday trading, down as much as 23.4%, before recovering to a 13.4% decline as of 3:25 p.m. EDT. The medical equipment company reported earnings last night that, on a headl...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 22.6% to $0.0461 on volume of 144,150,002 shares Vintage Wine Estates Inc. (VWE) rose 21.5% to $0.0849 on volume of 35,620,484 shares NVIDIA Corporation (NVDA) rose 2.4% to $115.03 on volume of 35,381,...